CSPC Pharmaceutical Group Ltd

1
HKSE:01093 (China)  
HK$ 6.52 (+4.82%) Apr 25
11.99
P/B:
2.14
Market Cap:
HK$ 77.56B ($ 9.91B)
Enterprise V:
HK$ 60.60B ($ 7.74B)
Volume:
40.61M
Avg Vol (2M):
42.22M
Also Trade In:
Volume:
40.61M
Avg Vol (2M):
42.22M
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for CSPC Pharmaceutical Group Ltd ( ) from 1994 to Apr 25 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. CSPC Pharmaceutical Group stock (HKSE:01093) PE ratio as of Apr 25 2024 is 11.99. More Details

CSPC Pharmaceutical Group Ltd (HKSE:01093) PE Ratio (TTM) Chart

To

CSPC Pharmaceutical Group Ltd (HKSE:01093) PE Ratio (TTM) Historical Data

Total 1192
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
CSPC Pharmaceutical Group PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-04-25 12.0 2024-02-19 11.2
2024-04-24 11.4 2024-02-16 11.4
2024-04-23 11.1 2024-02-15 11.0
2024-04-22 11.0 2024-02-14 11.0
2024-04-19 10.6 2024-02-09 10.8
2024-04-18 10.8 2024-02-08 11.0
2024-04-17 10.7 2024-02-07 11.1
2024-04-16 10.7 2024-02-06 11.3
2024-04-15 10.8 2024-02-05 10.6
2024-04-12 10.9 2024-02-02 10.7
2024-04-11 11.3 2024-02-01 10.7
2024-04-10 11.4 2024-01-31 10.6
2024-04-09 11.4 2024-01-30 10.8
2024-04-08 11.3 2024-01-29 10.9
2024-04-05 11.3 2024-01-26 11.0
2024-04-03 11.4 2024-01-25 11.2
2024-04-02 11.7 2024-01-24 10.9
2024-03-28 11.3 2024-01-23 10.6
2024-03-27 11.5 2024-01-22 10.4
2024-03-26 11.7 2024-01-19 10.9
2024-03-25 11.7 2024-01-18 11.2
2024-03-22 11.8 2024-01-17 11.0
2024-03-21 11.9 2024-01-16 11.2
2024-03-20 11.8 2024-01-15 11.7
2024-03-19 11.8 2024-01-12 12.0
2024-03-18 12.0 2024-01-11 11.9
2024-03-15 12.3 2024-01-10 12.7
2024-03-14 12.1 2024-01-09 12.8
2024-03-13 11.9 2024-01-08 12.8
2024-03-12 11.7 2024-01-05 13.2
2024-03-11 11.1 2024-01-04 13.5
2024-03-08 10.9 2024-01-03 13.1
2024-03-07 10.7 2024-01-02 13.2
2024-03-06 10.8 2023-12-29 13.3
2024-03-05 10.7 2023-12-28 13.3
2024-03-04 11.0 2023-12-27 12.2
2024-03-01 11.2 2023-12-22 12.1
2024-02-29 11.3 2023-12-21 12.0
2024-02-28 11.2 2023-12-20 12.1
2024-02-27 11.7 2023-12-19 12.1
2024-02-26 11.6 2023-12-18 12.3
2024-02-23 11.6 2023-12-15 12.4
2024-02-22 11.7 2023-12-14 12.1
2024-02-21 11.5 2023-12-13 11.7
2024-02-20 11.4 2023-12-12 11.6

CSPC Pharmaceutical Group Ltd (HKSE:01093) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Description
CSPC Pharmaceutical Group listed on the Hong Kong Stock Exchange in 1994 and is one of the largest pharmaceutical companies in China. Its biggest business segment is the finished drugs segment which accounts for nearly 80% of its total revenue. Now it has a diversified pipeline portfolio in seven therapeutic areas including nervous system diseases, oncology, anti-infective to cardiovascular disease, respiratory system disease, and metabolism. CSPC also has a bulk drug product segment including vitamin C, antibiotics, and a caffeine series.